S Aggarwal,
M Cudkowicz - Neurotherapeutics, 2008 - Springer
… Focused, early phase II studies defining dosage, pharmacodynamics, and drug interactions
will improve the likelihood of success for phase III trials. Additionally, understand barriers to …